Sorrento Therapeutics (SRNE) has plans to shortly advance its Bruton’s tyrosine kinase (Btk) inhibitor abivertinib into pivotal testing for the treatment of hospitalized COVID-19-infected patients, yet abivertinib has recently been making waves as a possible therapy for an entirely different disease. Last week, the peer-reviewed journal Clinical Cancer Research published the results from a pivotal study based in China in which abivertinib was tested on 227 heavily pretreated NSCLC (non-small cell lung cancer) patients. Out of 209 response evaluable patients, the confirmed overall response rate (ORR) came in at 52.2%, while the disease control rate (DCR) hit 88%. The median duration of response (DoR) was 8.
https://www.tipranks.com/news/article/with-progress-on-multiple-fronts-sorrento-stock-is-a-great-buy-analyst?utm_source=advfn.com&utm_medium=referral
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Sorrento Therapeutics Charts.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Sorrento Therapeutics Charts.